As weight loss medications containing active ingredients like semaglutide continue to define a new chapter in metabolic ...

Here's what to know about weight loss drugs such as Wegovy and Zepbound. CR helps you decide whether semaglutide or ...

Learn how the two forms of semaglutide compare in treating type 2 diabetes and supporting weight loss, plus their dosing ...

Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded ...

Metabolic/bariatric surgery is a highly effective treatment for people living with severe obesity and/or metabolic health ...

Apo-Semaglutide Injection™ is administered using a prefilled pen with instructions for use consistent with brand‑name semaglutide, supporting familiarity for patients and health care professionals, ...

TORONTO, May 14, 2026 /CNW/ - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based global health company, today announced the commercial launch of Apo‑Semaglutide Injection™ – a generic ...

Share on Pinterest The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy On April 30, 2026, the U.S. FDA announced it is considering ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, the latest move in a monthslong crackdown on the compounded GLP-1 market. The 503B bulks list ...

The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday.